ECO Animal Health plans to launch ECOVAXXIN MS poultry vaccine across the EU in 2026-2027
The vaccine protects against Mycoplasma synoviae infection which reduces egg production
Distribution covers 220 million layer birds across 7 EU countries
The vaccine is expected to contribute significantly to EBITDA by 2027/2028
📖 Full Retelling
London-based ECO Animal Health Group plc announced plans to launch its poultry vaccine ECOVAXXIN MS across the European Union throughout 2026 and 2027, following European Commission marketing authorization in December 2025, as the vaccine provides active immunization against Mycoplasma synoviae, an infection that can reduce egg production by 5-10% in affected laying hens. The company has secured distribution agreements covering markets with over 220 million layer birds annually across the EU's seven largest layer-producing countries. ECO will leverage its existing commercial network, established for its lead product Aivlosin, to distribute the vaccine throughout the region. An official launch event is scheduled for June 30 to July 1, 2026, in Madrid, Spain, with regional launch events planned between the third quarter of 2026 and first quarter of 2027. "This launch represents a significant milestone as the first product from ECO's proprietary R&D pipeline to be commercialized," said David Hallas, Chief Executive Officer. The company expects the vaccine sales to be margin accretive immediately and anticipates a material contribution to EBITDA for the 2027/2028 financial year. ECO is currently conducting distributor training programs, completing technical assessments, and preparing marketing materials ahead of the June launch event. The London-based company develops and markets veterinary pharmaceuticals globally, with marketing authorizations in over 70 countries and more than 200 employees worldwide.
Mycoplasma synoviae is a species of bacterium in the genus Mycoplasma. It causes disease in the joints, bones and respiratory system of birds. It is found throughout the world and infection may be referred to as infectious synovitis, avian mycoplasmosis, infectious sinusitis, or mycoplasma arthritis...
Animal vaccination is the immunisation of a domestic, livestock or wild animal. The practice is connected to veterinary medicine. The first animal vaccine invented was for chicken cholera in 1879 by Louis Pasteur.
The European Union (EU) is a supranational political and economic union of 27 member states that are located primarily in Europe. The union has a total area of 4,233,255 km2 (1,634,469 sq mi) and an estimated population of more than 450 million as of 2025. The EU is often described as a sui generis ...
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nasdaq ends more than 1% higher as Nvidia rises pre-earnings, tech extends rebound Gold prices head for fifth day of gains in six; JPMorgan sees more upside Nvidia set to report strong results and guidance, analysts say Selloff in this large IT stock offers a ’great buying opportunity into 2026’ (South Africa Philippines Nigeria) ECO Animal Health plans EU rollout for poultry vaccine By Investing.com Company News Published 02/26/2026, 02:24 AM ECO Animal Health plans EU rollout for poultry vaccine 0 EAH 0.00% LONDON - ECO Animal Health Group plc (AIM:EAH) announced plans to launch its poultry vaccine ECOVAXXIN MS across the European Union throughout 2026 and 2027, according to a press release statement. The vaccine provides active immunization of layer and breeder chickens from four weeks of age against Mycoplasma synoviae, an infection that can reduce egg production by 5-10% in affected laying hens. The European Commission granted marketing authorization for the product in December 2025. The company has secured distribution agreements covering markets with over 220 million layer birds annually across the EU’s seven largest layer-producing countries. ECO will use its existing commercial network, established for its lead product Aivlosin, to distribute the vaccine. An official launch event is scheduled for June 30 to July 1, 2026, in Madrid, Spain, with regional launch events planned between the third quarter of 2026 and first quarter of 2027. "This launch represents a significant milestone as the first product from ECO’s proprietary R&D pipeline to be commercialized," said David Hallas, Chief Executive Officer. The company stated it expects the vaccine sales to be margin accretive immediately and anticipates a material contribution to EBITDA for the 2027/2028 financial year. ECO is currently conducting distributor training programs, completing technical assessments, and preparing marketing materials ahead of ...
